CLINICAL TRIALS PROFILE FOR CLARAVIS

All Clinical Trials for Claravis

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	Children's Oncology Group	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00005576 ↗	Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 1	2001-01-01	Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation
NCT00025038 ↗	Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	2001-06-01	Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and fludarabine, before a donor bone marrow transplant or an umbilical cord transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. This phase II trial is studying how well giving combination chemotherapy together with donor bone marrow or umbilical cord blood transplant works in treating children with newly diagnosed juvenile myelomonocytic leukemia
NCT00026312 ↗	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2001-10-18	This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.

Clinical Trial Conditions for Claravis

Condition Name

Condition Name for Claravis
Intervention	Trials
Recurrent Neuroblastoma	8
Regional Neuroblastoma	6
Stage 4 Neuroblastoma	5
Stage 4S Neuroblastoma	5

Condition MeSH

Condition MeSH for Claravis
Intervention	Trials
Neuroblastoma	15
Ganglioneuroblastoma	5
Medulloblastoma	3
Neuroectodermal Tumors, Primitive	3

Clinical Trial Locations for Claravis

Trials by Country

Trials by Country for Claravis
Location	Trials
United States	439
Canada	50
Australia	20
New Zealand	6
Puerto Rico	5

Trials by US State

Trials by US State for Claravis
Location	Trials
California	18
Pennsylvania	17
Ohio	14
North Carolina	14
New York	14

Clinical Trial Progress for Claravis

Clinical Trial Phase

Clinical Trial Phase for Claravis
Clinical Trial Phase	Trials
Phase 3	8
Phase 2	4
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Claravis
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	7
Recruiting	3

Clinical Trial Sponsors for Claravis

Sponsor Name

Sponsor Name for Claravis
Sponsor	Trials
National Cancer Institute (NCI)	22
Children's Oncology Group	8
Comprehensive Cancer Center of Wake Forest University	1

Sponsor Type

Sponsor Type for Claravis
Sponsor	Trials
NIH	22
Other	10

Last updated: May 6, 2026

Clinical Trials Update and Market Outlook for CLARAVIS (Isotretinoin)

CLARAVIS is a branded oral isotretinoin product marketed by (or under the authorization of) Ascendis Pharma, Inc. for treatment of severe recalcitrant nodular acne. Its clinical development footprint is dominated by isotretinoin’s long-established standard-of-care profile rather than by a current, separately branded late-stage pipeline. Market dynamics are driven by generic competition, prescriber familiarity, REMS/SAFE dispensing constraints, and payor contracting for oral retinoids.

---

What is CLARAVIS and what is the clinical basis for use?

CLARAVIS (isotretinoin) is an oral retinoid indicated for severe recalcitrant nodular acne that has not responded adequately to conventional therapy. The drug’s clinical rationale is anchored in isotretinoin’s known mechanisms across:

• Reduced sebum production
• Normalization of follicular keratinization
• Anti-inflammatory and anti-Propionibacterium acnes activity
• Direct effects on sebaceous gland size and activity

Because isotretinoin is a mature therapy, “clinical trials update” for CLARAVIS typically means formulation/brand lifecycle events, labeling updates, and post-approval safety surveillance rather than a new Phase 3 readout for CLARAVIS itself.

---

What current clinical trial activity exists for CLARAVIS?

No current late-stage (Phase 2/3) CLARAVIS-specific pivotal trial readouts are identifiable from the provided information. The clinically actionable signal for an investable view is that isotretinoin remains a mature indication with widely available generic entry, which shifts the brand’s trial relevance toward:

• Bioequivalence and CMC-driven lifecycle changes
• Ongoing safety surveillance tied to the isotretinoin class
• Program adjustments tied to REMS compliance operationalization

Operational reality: for isotretinoin brands, the limiting factor is not new efficacy biology; it is risk management (iPLEDGE/REMS) and distribution contracting.

---

How does iPLEDGE/REMS shape access and competitive execution?

Isotretinoin is subject to strict pregnancy prevention and risk mitigation. In the US, iPLEDGE constrains prescribing, dispensing, and patient eligibility. Practically, this affects:

Access constraints

• Prescriber registration and patient enrollment workflows
• Monthly pregnancy testing requirements
• Dispensing timing windows
• Contraception compliance verification
• Age and pregnancy status checks

Business impact

• Lower tolerance for channel disruption and fulfillment failures
• Higher importance of pharmacy network execution
• Greater need for patient support operations

For CLARAVIS, brand differentiation is therefore less about “new clinical outcomes” and more about availability, adherence support, and payor positioning.

---

Where is the market headed for isotretinoin brands like CLARAVIS?

1) Generic pressure is the dominant structural force

Oral isotretinoin is widely available generically across multiple dosage strengths and pack formats. This typically compresses branded market share through:

• Lower net price under commercial contracting
• Higher switching when payors prefer generics
• Formulary tiering that reduces uptake of branded products

Branded brands typically retain share when they combine:

• Favorable formulary status in specific cohorts
• Strong specialty pharmacy distribution
• Reliability of supply
• Patient support and prescriber habit persistence

2) Patient need remains steady due to acne severity burden

Despite generics, the clinical need for severe recalcitrant nodular acne stays consistent. Isotretinoin utilization tracks largely with:

• Dermatology prescribing patterns
• Access to dermatology care
• Insurance coverage and prior authorization friction
• REMS workflow adherence

3) Forecast drivers for volume versus value

For branded isotretinoin, forecasts generally separate:

• Volume: stabilized by disease prevalence and consistent prescribing
• Value: pressured by generic price benchmarks and rebate structures

This yields a common outcome in mature generics-adjacent specialty pharmaceuticals: volume persistence, value erosion.

---

Market analysis: CLARAVIS competitive position and likely trajectory

Competitive landscape (structural)

• Primary competitor set: generic isotretinoin brands and private-label supply
• Secondary competitive force: alternative acne modalities (topicals, antibiotics, hormonal therapies) that may reduce the subset qualifying for isotretinoin, but do not eliminate the severe disease pool

Likely near-to-medium term trajectory for CLARAVIS

• Share pressure from generics through ongoing contracting cycles
• Net revenue stabilization attempts via:
  • specialty channel execution,
  • patient support for REMS adherence,
  • payer negotiations to maintain formulary presence
• Product lifecycle actions that do not require new efficacy endpoints

What matters most for projections (business levers)

• Net price vs. generic parity
• Formulary retention in commercial plans
• Switching rate by pharmacy benefits design
• Supply reliability (critical in controlled REMS distribution)
• Patient assistance and support cost effectiveness for REMS completion

---

Quantitative projections: what can be projected from the mature-isotretinoin setup?

A numeric forecast for CLARAVIS revenue, units, or market share cannot be produced from the provided information without specific dataset inputs (brand sales, market size, generic penetration by strength, payer coverage distribution, contract history). Under the constraints here, the only defensible projection is directional:

• Units: likely stable-to-slightly down relative to total isotretinoin demand due to generic switching.
• Revenue: likely down-to-flat due to net price compression.
• Profitability: depends on cost to serve REMS workflows, channel rebates, and manufacturing/pack economics.

This direction aligns with the typical lifecycle pattern for mature oral specialty medicines facing multi-source generic competition.

---

What clinical evidence supports continued use despite generics?

Even when new CLARAVIS-specific trials are not the driver, isotretinoin remains supported by:

• Long-term clinical consensus for severe recalcitrant nodular acne
• Established class safety profile managed through REMS
• Broad derm prescriber acceptance

From a decision standpoint, the “clinical trials update” for CLARAVIS is effectively the persistence of the clinical standard and ongoing safety risk mitigation, rather than new comparative efficacy evidence.

---

Key takeaways

• CLARAVIS is an isotretinoin brand for severe recalcitrant nodular acne; its clinical value is anchored in the long-established isotretinoin standard of care.
• “Clinical trials update” is not dominated by new CLARAVIS late-stage efficacy readouts; market-relevant changes are typically lifecycle, CMC, and REMS operational execution.
• Market outlook for a branded isotretinoin product is structurally constrained by generic competition, with the dominant risks in pricing and formulary placement and the dominant levers in channel reliability and REMS workflow support.
• Practical forecast direction: units stable-to-down, revenue under pressure unless CLARAVIS maintains favorable payer positioning.

---

FAQs

1. Is CLARAVIS a new-molecule development program?
   No. CLARAVIS is an isotretinoin brand in a mature, established therapy area with dominant generic pressure.

2. What is the main factor that affects CLARAVIS availability to patients?
   iPLEDGE/REMS compliance, which governs prescribing, enrollment, dispensing windows, and pregnancy prevention workflow.

3. Does CLARAVIS require new pivotal trials to remain marketed?
   No. Continued marketing relies on maintaining regulatory compliance and lifecycle approvals rather than new efficacy trials for investors’ near-term view.

4. How does generic isotretinoin typically impact branded products like CLARAVIS?
   It compresses net pricing and accelerates formulary switching, reducing branded share unless offset by payer placement and execution.

5. What should investors monitor to project CLARAVIS performance?
   Net price trends, formulary retention by payer segment, specialty pharmacy distribution reliability, and REMS workflow cost-to-serve.

---

References (APA)

1. US Food and Drug Administration. (n.d.). iPLEDGE REMS information and isotretinoin risk management requirements. https://www.ipledgeprogram.com
2. DailyMed. (n.d.). CLARAVIS (isotretinoin) prescribing information. https://dailymed.nlm.nih.gov
3. US Food and Drug Administration. (n.d.). Drug trials snapshots and labeling resources for isotretinoin products. https://www.accessdata.fda.gov/scripts/cder/daf/